Chlorambucil dosage in frequently relapsing nephrotic syndrome: a controlled clinical trial.

Abstract

A controlled clinical trial was performed using two dosage regimens of chlorambucil to treat children with frequently relapsing nephrotic syndrome. All children concurrently received prednisone (60 mg/m2 on alternate days). Ten children (Group I) were given chlorambucil as a stable dose (0.2 mg/kg/day) for 56 to 60 days, and 11 children (Group II) received increasing doses (0.2 to 0.63 mg/kg/day) for 42 to 77 days. Two children in each group subsequently relapsed. Follow-up averaged 28.6 and 27.2 months in Groups I and II, respectively. Three children in Group II developed infectious complications. The data indicate that a stable dosage regimen for chlorambucil is as effective as an increasing dose regimen in achieving long-term remission of frequently relapsing nephrotic syndrome.

• Authors: H J Baluarte, L Hiner, A B Gruskin
• Journal: The Journal of pediatrics (J Pediatr) Vol. 92 Issue 2 Pg. 295-8 (Feb 1978) ISSN: 0022-3476 [Print] United States
• PMID: 621612 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Chlorambucil

Topics

• Adolescent
• Child
• Child, Preschool
• Chlorambucil (administration & dosage, adverse effects, therapeutic use)
• Humans
• Nephrotic Syndrome (drug therapy)
• Recurrence
• Remission, Spontaneous